Clinical Trial

CPX-351 as a Novel Approach for the Treatment of Older Patients With AML and MDS

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate how effective lower doses of CPX-351 are in older participants with relapsed/refractory acute myeloid leukemia (AML) who are not eligible to receive intensive chemotherapy and in participants with myelodysplastic syndromes (MDS) after Hypomethylating Agents (HMA) failure.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2020-12-14; most recent amendment 2026-06-11.
Status change: Recruiting → Active, Not Recruiting 2022-11-08
Status change: Not Yet Recruiting → Recruiting 2021-01-19
Trial Details
NCT Number NCT04668885
Lead Sponsor Case Comprehensive Cancer Center
Conditions Refractory Acute Myeloid Leukemia, Relapsed Acute Myelomonocytic Leukemia, Myelodysplastic Syndromes
Enrollment 13 participants
Start Date 2021-01-14
Primary Completion 2026-01-19 (estimated)
Study Completion 2027-01-19 (estimated)
Updated on ClinicalTrials.gov 2026-06-12